Quick context
GHRP-6
Is studied for growth-hormone release and appetite-related ghrelin signalling.
No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.
Back to all 64 profiles
Community/research information onlyNot FDA/EMA approvedWADA
Community protocol · GHRP-6
GHRP-6: community information and evidence, clearly separated.
A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.
Also known as: Growth hormone-releasing peptide 6
Sources checked: 27 August 2026
Important safety and liability notice
This page documents and evaluates online community information. It is not medical or therapeutic advice, individual counselling or an invitation to use Ipamorelin. It is not approved for the uses described here.
No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.
Amounts, timing and cycles
Community/research information only
No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.
Amount status
Different amounts circulate online; no regulator-confirmed safe or effective dose exists.
Profile evidence level: early_human.
Timing
Community claims about time of day, fasting windows or training intervals are not validated clinical standards.
No individual recommendation.
Cycle/duration
Cycles and breaks are community constructs and do not prevent adverse effects or unknown long-term consequences.
No individual recommendation.
External community reference available
The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.
Open community sourceReconstitution and U-100 conversion
Reconstitution calculator
For clearly identified single lyophilised substances, the calculator only shows the arithmetic between vial amount, liquid volume and target amount. It does not check identity, purity, sterility, solubility, stability or solvent suitability. The entered target is not a recommendation.
Reconstitution calculator
Calculates concentration, volume and theoretical U-100 units. The preloaded 200 µg is only the reference page's arithmetic example.
Concentration
3,333.33 µg/ml
Calculated volume
0.06 ml
U-100 units
6 U
Calculated portions per vial
50
Calculation aid, not dosage or use advice. Incorrect inputs, a different syringe scale, measurement error, dead space or unknown vial content produce incorrect results.
Mechanism and research questions
Ghrelin receptor agonist and GH secretagogue
GHRP-6 is classified as “Ghrelin receptor agonist and GH secretagogue”. Is studied for growth-hormone release and appetite-related ghrelin signalling. This describes the investigated pathway but does not validate a community use, amount, route or combination.
Ghrelin secretagogue
This checks how a substance stimulates growth hormone release through the ghrelin receptor, similar to how the body's own hunger hormone does. Measures include growth hormone peaks in blood and appetite changes.
Growth hormone release
This studies how much growth hormone the pituitary gland releases into the blood after a stimulus, similar to measuring how much water flows out when a tap is briefly opened. Researchers typically draw blood samples at several time points to capture the size and timing of the release.
Growth-axis amplification
Researchers study how a substance amplifies the natural hormone chain from brain to pituitary to growth hormone, rather than supplying growth hormone directly. Hormone levels over time and muscle or fat mass are measured.
What communities discuss
These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.
Bodybuilding forums
Here, muscle growth, strength gains, and recovery times are compared between different growth and repair peptides, often based on personal training logs. Vendor and user claims about muscle gains are anecdotal experience, not controlled study results.
Doping and sports forums
The use of performance-enhancing peptides in sport is discussed, including experiences with competition testing and regulatory ban lists. Personal experience does not establish efficacy or safety and does not replace official rule checks.
Source and purity discussion
Discussion covers which vendors are seen as more trustworthy and how purity test results differ between batches. Such community assessments are based on limited samples and do not replace independent lab testing of each individual batch.
Adverse effects and risk boundaries
- Interference with GH, IGF-1 or other hormone axes may cause oedema, joint or nerve symptoms, glucose intolerance, blood-pressure and hormonal changes; dependable human data are absent for many research substances.
- Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
- A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.
Exclusion groups and professional assessment
- Active or previous malignancy, uncontrolled diabetes, intracranial disease, pregnancy/breastfeeding and hormone-sensitive disease require specialist assessment; approved products have specific contraindications.
- Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
- Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.
Monitoring and laboratory markers
- In medically justified use, IGF-1, fasting glucose/HbA1c, blood pressure, weight/oedema, thyroid and indication-specific hormones may be relevant; this is not a self-testing schedule.
- Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.
Evidence boundary
Early human data
Human data are limited; the FDA identifies possible changes in cortisol and blood glucose among the safety questions.
Published evidence
Some early, usually small human studies or observations exist, but they do not yet count as robust proof of efficacy.
GHRP-6 is particularly linked to ghrelin-related appetite signalling, distinguishing it from analogues focused purely on growth hormone.
Storage and stability
- The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
- Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
- Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.
Troubleshooting and error sources
- U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
- Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
- Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
- Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.
Regulatory status and WADA
Not FDA/EMA approved
No FDA- or EMA-approved medicinal product; efficacy and safety are not established.
WADA 2026
This profile is marked as WADA-relevant. Check the original 2026 Prohibited List and the specific sport/route; a prohibition may cover an entire class or related agents.
WADA — 2026 Prohibited ListComparisons and related profiles
Combinations / stacks
- Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
- Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
- Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.
Frequently asked questions
Is an amount shown here a recommendation?
No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.
Does the U-100 calculator prove correct use?
No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.
Can this profile be combined with other substances?
Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.
Which source controls when information conflicts?
For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.
Are community claims clinical evidence?
No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.
Sources and evidence layers
Primary sources and official registries take priority. The community reference is labelled separately.
- Primary/technical sourceFDA: peptide compounding safety review
- Primary/technical sourceWADA: 2026 prohibited list
- Community referenceGHRP-6 — Peptide Dosing Protocols